Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
Free accessResearch articleFirst published online April, 2015
Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
Here, the baseline and emergent resistance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) versus efavirenz (EFV)/FTC/TDF in HIV-1-infected antiretroviral-naive adults through 144 weeks from the randomized, ongoing, Phase III study GS-US-236-0102 is described.
Methods
HIV-1 protease (PR) and reverse transcriptase (RT) were sequenced at screening; patients with HIV-1 resistant to EFV, FTC or TDF were excluded. Genotypic/phenotypic analyses were performed at virological failure confirmation and baseline for PR, RT and integrase (IN) for patients with virological failure and for patients with HIV-1 RNA≥400 copies/ml at weeks 48, 96, 144 or early study drug discontinuation. Retrospective, baseline, IN genotyping was conducted for EVG/COBI/FTC/ TDF patients.
Results
In the EVG/COBI/FTC/TDF group through week 144, HIV-1 from 10 patients (2.9%; 10/348 treated patients) developed primary IN strand transfer inhibitor (n=9) and/or nucleoside RT inhibitor resistance substitutions (n=10). The emergence of resistance decreased over time with 8, 2 and 0 patients developing HIV-1 resistance through week 48, post-week 48–96 and post-week 96–144, respectively. Emergent substitutions were E92Q (n=7), N155H (n=3), Q148R (n=1) and T66I (n=1) in IN, and M184V/I (n=10) and K65R (n=4) in RT. All 10 isolates had reduced susceptibility to EVG, FTC or TDF. Virus with EVG phenotypic resistance had cross-resistance to raltegravir. In the EFV/ FTC/TDF group, virus from 14 patients (4.0%; 14/352 treated patients; 4 during weeks 96–144) developed a resistance substitution to EFV (n=14; K103N: n=13), FTC (M184V/I: n=4) or TDF (K65R: n=3).
Conclusions
Resistance development to EVG/COBI/FTC/ TDF was infrequent through 144 weeks of therapy and decreased over time, consistent with durable efficacy.
References
1.
GermanP., WarrenD., WestS., HuiJ., KearneyB.P.Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.J Acquir Immune Defic Syndr2010; 55: 323–329.
2.
ShimuraK., KodamaE., SakagamiY.Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).J Virol2008; 82: 764–774.
3.
McCollD.J., ChenX.Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.Antiviral Res2010; 85: 101–118.
4.
AbramM.E., HluhanichR.M., GoodmanD.D.Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.Antimicrob Agents Chemother2013; 57: 2654–2663.
5.
MathiasA.A., GermanP., MurrayB.P.Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.Clin Pharmacol Ther2010; 87: 322–329.
6.
SaxP.E., DeJesusE., MillsA.Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks.Lancet2012; 379: 2439–2448.
7.
ZolopaA., SaxP.E., DejesusE.A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/ emtricitabine/tenofovir DF versus efavirenz/emtricitabine/ tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.J Acquir Immune Defic Syndr2013; 63: 96–100.
8.
WohlD.A., CohenC., GallantJ.E.A randomized, double-blind comparison of single-tablet regimen elvitegravir/ cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 Infection: analysis of week 144 results.J Acquir Immune Defic Syndr2014; 65: e118–e121.
9.
PetropoulosC.J., ParkinN.T., LimoliK.L.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.Antimicrob Agents Chemother2000; 44: 920–928.
10.
JohnsonV.A., CalvezV., GunthardH.F.2011 update of the drug resistance mutations in HIV-1.Top Antivir Med2011; 19: 156–164.
11.
BennettD.E., CamachoR.J., OteleaD.Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.PLoS ONE2009; 4: e4724.
12.
VargheseV., LiuT.F., RheeS.Y.HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir.AIDS Res Hum Retroviruses2010; 26: 1323–1326.
13.
MargotN.A., EnejosaJ., ChengA.K., MillerM.D., McCollD.J.Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.J Acquir Immune Defic Syndr2009; 52: 209–221.
14.
MolinaJ.M., LamarcaA., Andrade-VillanuevaJ.Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, Phase 3, non-inferiority study.Lancet Infect Dis2012; 12: 27–35.
15.
LennoxJ.L., DejesusE., BergerD.S.Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.J Acquir Immune Defic Syndr2010; 55: 39–48.
16.
LennoxJ.L., DeJesusE., LazzarinA.Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.Lancet2009; 374: 796–806.
17.
EronJ.J.Jr., RockstrohJ.K., ReynesJ.Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, Phase 3 non-inferiority trial.Lancet Infect Dis2011; 11: 907–915.
18.
DeJesusE., RockstrohJ., HenryK.Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3, non-inferiority trial.Lancet2012; 379: 2429–2438.
19.
RaffF., RachlisA., StellbrinkH.J.Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.Lancet2013; 381: 735–743.
20.
WalmsleyS.L., AntelaA., ClumeckN.Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.N Engl J Med2013; 369: 1807–1818.
21.
ClotetB., FeinbergJ., van LunzenJ.Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label Phase 3b study.Lancet2014; 383: 2222–2231.
22.
SvarovskaiaE.S., FengJ.Y., MargotN.A.The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.J Acquir Immune Defic Syndr2008; 48: 428–436.
23.
XuL., LiuH., MurrayB.P.Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer.ACS Med Chem Lett2010; 1: 209–213.
24.
BoothC.L., GerettiA.M.Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.J Antimicrob Chemother2007; 59: 1047–1056.
25.
Tivicay (dolutegravir).US prescribing information 2013.GlaxoSmithKlineResearch Triangle Park, NC, USA.
26.
EronJ.J., ClotetB., DurantJ.Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.J Infect Dis2013; 207: 740–748.
